Pfizer Lilly: Different Bets on Pharma M&A Explained
Eli Lilly posts a blockbuster start to 2026 as Pfizer works to rebuild after the COVID era, highlighting pfizer lilly...
Discover timing cues for using tactical allocation with index funds retirement to potentially enhance returns without sacrificing core diversification.
23,450 articlesEli Lilly posts a blockbuster start to 2026 as Pfizer works to rebuild after the COVID era, highlighting pfizer lilly...
Berkshire Hathaway underperforming vs the S&P 500 in 2026, even as Warren Buffett’s top holdings rise. A look at why ...
Western Digital stock has surged on AI storage demand and margin gains. Analysts debate if western digital corporatio...
Meta faced a pivotal near-miss in 2026 as it stepped back from a Kalshi deal. The decision highlights how regulatory ...
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
In Buffett's final chapters as Berkshire's CEO, one move stood out: selling a stock that helped build his fortune. Th...
UBS analysts view Target's planned $2 billion investment for 2026 as a bold, two-pronged turnaround bet. The plan spl...
Chevron reports stronger-than-expected Q1 2026 results and advancing Hess synergy-driven production, but investors de...
Hormel (HRL) 2026 earnings continue to show resilience in a volatile consumer environment. This deep dive breaks down...
As Wiley (WLY) gears up for its 2026 earnings, investors should focus on segment growth, margin trajectory, and the c...
P&G leads with broad-based growth and new investments across beauty and global markets, while Colgate-Palmolive leans...
IBM recently released a preliminary quarter that underscored a broader pattern: AI budgets are shifting. This article...